We are honored to announce that Prof. Dr. A. Douglas Kinghorn will serve as the Chair of the 2024 Tu Youyou Award Committee.

Name: Prof. Dr. A. Douglas Kinghorn
Affiliation: College of Pharmacy, The Ohio State University, USA

Prof. Dr. Kinghorn is a leading expert in pharmacognosy and natural products research. He is recognized for his key contributions to discovering bioactive compounds from plants, especially in anticancer, cancer chemopreventive, and substances with a sweet taste and taste-modifying agents. His prolific contributions include over 590 peer-reviewed works and edited or co-edited 40 scientific volumes.

The 2024 Tu Youyou Award Committee, under Prof. Dr. Kinghorn's guidance, will focus on identifying innovative research in the fields of natural products chemistry and medicinal chemistry. The committee will aim to identify groundbreaking work with the potential to lead to significant advancements in these areas.

We are confident that, with Prof. Dr. Kinghorn at the helm, the 2024 Tu Youyou Award will continue to inspire excellence and innovation in the related fields.

About the Tu Youyou Award
Established in 2016, the Tu Youyou Award seeks to honor those who excel in the fields of natural products chemistry and medicinal chemistry. This award offers a total prize of CHF 100,000, which will be equally divided among the winners if there is more than one, with each recipient receiving an award medal.

The 2024 Tu Youyou Award remains open for nominations until 31 December 2024. We encourage all eligible candidates to participate in this prestigious recognition, as this award not only honors individual achievement but also encourages further scientific exchange, exploration and discovery in critical areas of medicine.

If you are interested in participating, please visit the Tu Youyou Award website for more information on the nomination requirements.

Five new journals covering a diverse range of subjects launched their inaugural issue in September 2024. Like other journals in MDPI’s portfolio, these journals are dedicated to sharing the latest research through open access, reflecting our commitment to making knowledge accessible to all.

We extend our sincere gratitude to the Editorial Board Members for their dedication to the launch and development of our new journals. Each journal will ensure its high-quality output via excellent editorial and rigorous peer-review processes so that the published articles achieve significant impact and broad visibility.

We invite you to explore and learn more about these new journals below.

Journal	Founding Editor-in-Chief	Journal Topics (Selected)
	Prof. Dr. Nejat Düzgüneş, University of the Pacific, USA | Editorial | view inaugural issue	biological therapy and stem-cell therapy; drug therapy; chemotherapy; radiation and other nonsurgical therapeutic strategies | view journal scope | submit an article
	Prof. Dr. Magda Tsolaki, Greek Federation of Alzheimer’s Disease, Greece; Aristotle University of Thessaloniki, Greece | Editorial | view inaugural issue	surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article
	Prof. Dr. Steven R. Fassnacht, Colorado State University, USA; Cooperative Institute for Research in the Atmosphere, USA | Editorial | view inaugural issue	ice as a mineral; atmospheric ice; sea ice; freshwater ice; ice sheets; ice caps and ice shelves | view journal scope | submit an article
	Dr. Francisco Epelde, Hospital Universitari Parc Tauli, Spain; University Autonoma of Barcelona, Spain | Editorial | view inaugural issue	hospital management; hospital facilities; hospital services; hospital risk management; health law | view journal scope | submit an article
	Prof. Dr. Nicola Ferri, University of Padova, Italy | Editorial | view inaugural issue	lipids in cells and whole organisms; lipid structure and function; lipid products and processes; dietary lipids and nutrition | view journal scope | submit an article

We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here or contact the New Journal Committee ([email protected]) if you would like to create more new journals.

As a leader in open access publishing, MDPI is eager to explore new collaboration opportunities, including the launch of new journals and the transfer of existing ones. At present, MDPI publishes over 400 journals, more than 160 of which have established partnerships with academic organizations. Additionally, we publish 19 association journals.

In order to enhance exchange and cooperation with scientific researchers and share the results of open science, MDPI invites experts and scholars from various fields to submit proposals for new journal collaboration opportunities. If your proposal is approved, you could take on the role of Editor-in-Chief, Deputy Editor-in-Chief, or Editorial Board Member of the journal. This position allows you to manage the manuscript review process alongside our editorial department, participate in calls for papers, strengthen your network with scholars in the field, expand scientific research cooperation, enhance your personal and academic influence internationally, and play a leading role in academia.

Once the new journal is online, MDPI will provide a variety of promotional channels to market the journal internationally.

MDPI will offer various promotional channels to enhance its visibility and promote it internationally.

How can you determine the theme of a new journal?

• Assess research hotspots/academic frontiers;
• Assess pioneers in the field/key research directions of universities;
• Determine whether MDPI has already established a journal in the field.

You can browse MDPI’s existing journals at the following link: https://www.mdpi.com/about/journals.

Advantages of collaborating with MDPI:

• MDPI is a global leader in open-access publishing with extensive academic resources.
• MDPI offers a professional publishing team that provides comprehensive support throughout the publishing process.
• MDPI’s diverse promotional platforms and channels help journals quickly increase their international visibility and influence.

We invite you to submit new journal proposal here, and contribute to academic development! In addition, if your institution (university, institute, college, national key laboratory, society, etc.) intends to establish a journal, you can also submit a draft to MDPI on its behalf.

MDPI journals frequently grant travel awards to empower junior researchers to showcase their latest research at academic conferences, thereby amplifying their impact within their research fields.

We extend our heartfelt congratulations to the 103 recipients of MDPI's 2023 Travel Awards from different countries and territories for their exceptional presentations. These outstanding individuals were selected by the journal editors based on the strength of their research proposals and the anticipated impact of their presentations at academic conferences. We commend their exceptional contributions and wish them continued success in their academic endeavors.

MDPI will continue to provide support and recognition to the academic community. To learn more about the list of awardees, please visit the following pages:

• Biology and Life Sciences;
• Chemistry and Materials Sciences;
• Engineering;
• Environmental and Earth Sciences;
• Medicine and Pharmacology;
• Public Health and Healthcare;
• Others.

About MDPI Awards:

To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.

To explore more MDPI awards, please click here.

We are pleased to announce that the Journal of Pharmaceutical and BioTech Industry (JPBI, ISSN: 2813-9380) has established a companionship with its sister journal, Pharmaceutics (ISSN: 1999-4923).

The Journal of Pharmaceutical and BioTech Industry is an international, peer-reviewed, and open access journal committed to publishing research and development studies on all aspects of science, engineering, and technology applicable to the pharmaceutical and biotech industry sectors, published quarterly online by MDPI. The founding Editor-in-Chief is Prof. Dr. Ecevit Bilgili from the New Jersey Institute of Technology, USA.

The Journal of Pharmaceutical and BioTech Industry aims to create a platform on which scientists and engineers from academia, industry, and regulatory as well as other governmental agencies share and complement each other’s discoveries and advance science, engineering, and technology with the goal of enhancing patient wellbeing. All aspects of the discovery, development, delivery, and manufacturing of drugs (drug substances and drug products, including biodrugs, delivery devices, diagnostic agents, etc.) are covered. We accept original research articles, critical and timely reviews, short communications, opinions, technical notes, reports, and expert perspectives. For details on the background and scope of this journal, please click on the following link: https://www.mdpi.com/journal/jpbi/about.

We offer a full waiver on article processing charges for papers submitted before 1 January 2025. Manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 5.8 days (median values for MDPI journals in the first half of 2024). If accepted after peer review, your paper will be published in an open access format.

Manuscripts can be submitted via the journal’s online submission system at the following link: https://susy.mdpi.com/user/manuscripts/upload?journal=jpbi.

You can read the Opening Editorial by the Editor-in-Chief at the following link: https://www.mdpi.com/2813-9380/1/1/3.

You can read the short interview with Prof. Dr. Ecevit Bilgili, the Editor-in-Chief, who shared his vision for the journal with us, as well as his views of the area and open access publishing: https://www.mdpi.com/journal/jpbi/announcements/9313.

We cordially invite you to consider the Journal of Pharmaceutical and BioTech Industry as the platform for publishing your work.

JPBI Editorial Office

MDPI’s Best PhD Thesis Awards are granted to promising young scholars whose PhD theses are deemed exceptional within their respective research fields. These awards aim to encourage young scholars to continue their outstanding accomplishments and further contribute to their field.

We extend our heartfelt congratulations to the 54 winners of the 2023 Best PhD Thesis Awards and wish them success with their future research endeavors.

MDPI will continue to provide support and recognition to the academic community. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:

About MDPI Awards:

To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.

To explore more MDPI awards, please click here.

Conference: The 33rd Annual Conference Biomaterials in Medicine and Veterinary Medicine
Date: 10–13 October 2024
Location: Rytro, Poland
Conference homepage: https://www.biomat.agh.edu.pl/

The annual conferences on Biomaterials in Medicine and Veterinary Medicine organized by the Polish Society for Biomaterials address both the fundamentals and clinical applications of carbon, metals, polymers, ceramics and composite biomaterials. Their aim is to present the latest results of scientific research and to provide a platform for the exchanging of ideas, knowledge and experiences with scientists, researchers and clinicians in the field of biomaterials.

This year, the conference will be held from 10 to 13 October 2024 in Rytro, Poland. Excellent plenary speakers have been invited, such as Prof. Małgorzata Włodarczyk-Biegun, Prof. Sachiro Kakinoki, and Prof. Miguel Oliveira, to share their passion and knowledge with conference participants. Podium and poster presentations will allow our presenters to showcase their latest research. Also, Best Poster and Rapid-Fire Presentation Competitions are planned for early career scientists. Finally, in addition to the high-quality scientific elements, a rich cultural and social program is offered for attendees to enjoy throughout the conference (all included in the fee).

Abstracts for late posters can be still submitted from 26–31 August 2024.

Conference: The 15th APS PharmSci International Conference
Date: 4–6 September 2024
Location: Huddersfield, UK
Conference homepage: https://apspharmsci.com/

The Academy of Pharmaceutical Sciences (APS) is a UK-based professional membership body for pharmaceutical scientists. We represent individuals and organizations from around the globe, helping them throughout their development, ensuring consistently excellent delivery in the Pharmaceutical Science sector. Pharmaceutical scientists are experts in the research, development and manufacturing of medicines. They have a major role in the regulation of medicines and understanding their use in patients.

The aim of the 2024 APS conference is to provide a forum for the presentation and exchange of ideas relating to the latest high-quality developments in the design and manufacturing of new medicines from discovery to commercialization. The conference will provide a dynamic forum for members of industry, both large and small, to come together with academic colleagues to explore new technologies and processes. Collaboration and cooperation is the key to modern pharmaceutical development, and the University of Huddersfield will provide an ideal setting to bring together groups from across Ireland, the UK and beyond to showcase internationally leading work and to set the stage for a new era of pharmaceutically driven healthcare.

MDPI’s Young Investigator Awards recognize promising early career scientists, acknowledge their contributions, and foster collaboration within the scientific community. We are proud to announce the recipients for 2023, who were carefully selected by the journals’ esteemed Award Evaluation Committee.

We extend our heartfelt congratulations to the 79 winners of MDPI’s 2023 Young Investigator Awards for their excellent contributions in their research field. We look forward to seeing these rising stars continue to contribute to the advancement of science.

MDPI will continue to support and recognize the academic community. To explore details about the awardees by field, please visit the individual pages listed below:

Congratulations to all the winners for their exceptional contributions and dedication to advancing scientific research.

About MDPI Awards:
To support the academic community, particularly young researchers, and to enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help to elevate the profiles of talented individuals who have made outstanding achievements and are making significant contributions to advancements in their respective fields.

To find out more about MDPI awards, please click here.

Conference name: 22nd International Nanomedicine and Drug Delivery Symposium (NanoDDS 2024)
Date: 13–15 September 2024
Location: Orlando, FL, USA
Conference homepage: https://pharmacy.ufl.edu/nanodds/

Pharmaceutics (ISSN: 1999-4923) is now collaborating with the 22nd International Nanomedicine and Drug Delivery Symposium, or nanoDDS, which will be held in Orlando, FL, USA from 13 to 15 September 2024. The annual event serves as an important gathering for researchers developing next-generation delivery vehicles—targeted, responsive, biodegradable nanomaterials to make diagnostics more sensitive and drugs more effective. Established in 2003 by Dr. Alexander Kabanov and Dr. Kazunori Kataoka, the symposium has attracted more than 3,000 participants from 30 different countries over the years and has become one of the most authoritative forums in its field.

We invite you to join this excellent event and communicate with the top experts in the community.

In May, MDPI Romania held three author training sessions – one endorsing an external event and two stand-alone sessions.

The National Session of Scientific Student Communications took place at Technical University Cluj on 17 and 18 May 2024. MDPI Romania sponsored this event and contributed an author training session on the production of research papers and case study analyses. JRS Norbert Kiss gave a presentation called The World of Open Access to explain different open access publishing models and the benefits of open access publishing. His presentation highlighted the impact of open access publishing on scientific progress and innovation.

On 29 May 2024, MDPI Romania hosted an author training session for Ph.D. students, early career researchers, and professors at the Carol Davila University of Medicine and Pharmacy. In collaboration with Prof. Andreea Arsene, JRS Ioana Paunescu prepared two presentations: The Steps of the Publishing Process and Elaboration of a Peer Review Report. In her first presentation, she delved into MDPI’s history and mission, MDPI’s editorial process, and MDPI journals of various scopes that are accepting submissions. Her second presentation outlined the types of peer review, the contents of a peer review report by an MDPI reviewer, and the responsibilities of an MDPI reviewer.

MDPI Romania also hosted an author training session at the Iasi University of Life Sciences on 29 May 2024. JRSs Laurentiu Preda and Cosmin Artan gave four presentations: Efficient Writing of an ISI-Indexed Scientific Article, Benefits of Publishing in the Open Access Model, Various Methods of Open Access Publishing, and MDPI Guide for the Article Review Process. The first three presentations offered guidance on how to improve academic writing, the fourth focused on how to write peer review reports. A highly interactive discussion followed the presentations, during which the JRSs provided extensive answers to attendees’ questions.

MDPI is grateful for all the attendees, speakers, and organizers involved in these events. Through their enthusiasm and dedication, these events were great successes.

We are pleased to announce that Pharmaceutics (ISSN: 1999-4923) has entered into a collaboration with the Korean Society of Pharmaceutical Sciences and Technology (KSPST) for two significant upcoming events:

2024 International Conference of the Korean Society of Pharmaceutical Sciences and Technology
Date: 26–28 November 2024
Location: Seoul, Republic of Korea

The above conference aims to highlight recent breakthroughs and innovative achievements in pharmaceutical sciences and technology, with a particular emphasis on critical advancements and the application of diverse technologies to bridge the gap between basic research and clinical application. The scientific sessions will cover a wide range of topics, including formulation development, regulatory science, drug delivery, and pharmaceutical manufacturing technology. Additionally, the conference will feature oral sessions for young scientists and poster oral presentations, offering valuable opportunities for them to present their work and engage with experts in the field. The above conference also provides a great chance for multi-disciplinary researchers from academia, research institutes, the pharmaceutical industry, and government sectors to engage in fruitful scientific discussions, fostering global collaborations and networking.

2024 Formulation Technology Workshop
Date: 20 September 2024
Location: Seoul, Republic of Korea

Since its establishment in 1971, the Korean Society of Pharmaceutical Sciences and Technology (KSPST) has been at the forefront of advancing pharmaceutical sciences. The KSPST has dedicated itself to facilitating the prompt dissemination of academic research outcomes and the industrial application of innovative science by organizing regular scientific events.

If you plan to attend either or both of these events, we would appreciate it if you could let us know your availability. The journal looks forward to the opportunity to meet with you and explore new avenues for mutual growth and development.

The 8th China-Europe Symposium on Biomaterials in Regenerative Medicine will be held from 15 to 18 September 2024, in Nuremberg, Germany. The conference is organized by Chinese Society for Biomaterials (CSBM) and European Society for Biomaterials (ESB).

Topics include the following:

• Advanced metallic biomaterials;
• Natural and synthetic polymers;
• Bioceramics in regenerative medicine;
• Advanced biocomposites;
• Multi-functional hydrogels;
• Nanomaterials and nanomedicine;
• Biomaterials for bone regeneration;
• Biomaterials for cartilage regeneration;
• Biomaterials for nerve regeneration;
• Vascular regeneration biomaterials;
• Biomaterials in cancer microenvironment;
• Marine biomaterials;
• Biomaterials surfaces and interfaces;
• Characterization and assessment of biomaterials;
• Bio-imaging and molecular probe;
• Cardiovascular biomaterials;
• Dental biomaterials;
• Biomaterials for drug delivery systems;
• Biomaterials for in vitro disgnostics.

The following MDPI journals will be represented in the conference:

• Journal of Functional Biomaterials;
• Gels;
• Bioengineering;
• Fibers;
• Journal of Composites Science;
• Materials;
• Macromol;
• Coatings;
• Pharmaceutics.

If you are attending this conference, please feel free to start a conversation with us by contacting us online. Our delegates look forward to meeting you in person at a booth and answering any questions that you may have. For more information about the conference, please visit the following link: https://www.cesb2024.org/.

Five new journals covering multiple subjects have launched their inaugural issue in June 2024. We are excited to be able to share with you the newest research rooted in the value of open access.

We would like to express our deepest appreciation to all the Editorial Board Members and each journal will ensure its high-quality output using excellent editorial and rigorous peer review processes, to ensure that the articles achieve high impact and visibility.

Please feel free to browse and discover more about the new journals below.

Journal	Founding Editor-in-Chief	Journal Topics (Selected)
	Prof. Dr. Marco Ranucci, IRCCS Policlinico San Donato, Italy | Editorial | view inaugural issue	anaesthetic medications; blood and fluid management; pain management; critical care; critical illness | view journal scope | submit an article
	Dr. Giovanni E. Cacciamani, University of Southern California, USA | Editorial | view inaugural issue	surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article
	Prof. Dr.  Gassan Hodaifa, Universidad Pablo de Olavide, Spain | Editorial | view inaugural issue	laboratory management; laboratory safety; protective equipment; laboratory problems and challenges; laboratory Innovation | view journal scope | submit an article
	Prof. Dr. Jan S. Suchodolski, Texas A&M University, USA | Editorial | view inaugural issue	companion animals health and disease; veterinary care and nutrition; genetics and genomics; behavior and welfare; human-animal relations | view journal scope | submit an article
	Prof. Dr. Pierfrancesco De Paola, University of Naples Federico II, Italy | Editorial | view inaugural issue	real estate appraisal; economic and financial valuation of real estate projects; sustainable real estate; housing and urban economics | view journal scope | submit an article

We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here, or contact the New Journal Committee ([email protected]) if you would like to create more new journals.

Conference: the CRS 2024 Annual Meeting and Expo (CRS 2024)
Date: 8–12 July 2024
Location: Bologna, Italy

This conference will be the 51st annual conference of the Controlled Release Society. The annual CRS conference is the most important one in the pharmaceutics field. The main topics of the conference include Nanomedicine and Nanoscale Delivery, Immuno Delivery, Oral Delivery, Skin and Mucosal Delivery, Ocular Delivery, Bioengineering, Gene Delivery and Gene Editing, Alternative Methods to Animal Testing, Long-Acting Drug Delivery Formulations, Delivery to the Nervous System, Artificial Intelligence, and Predictive Models in Pharmaceutical Technologies.

MDPI will be attending the CRS 2024 Annual Meeting and Expo (CRS 2024). We welcome researchers from different backgrounds to visit and share their latest ideas with us.

The following MDPI journals will be represented:

• Pharmaceutics;
• Molecules;
• Pharmaceuticals;
• Future Pharmacology;
• Applied Biosciences;
• IJMS;
• Gels;
• BioMedInformatics;
• CIMB;
• JNT;
• Life;
• Biomolecules.

If you plan to attend this conference, please contact us online. Our delegates look forward to meeting you in person at booth #29 and answering any questions you may have. For more information about the conference, please visit the following website:  https://2024crsannualmeeting.eventscribe.net/.

We are thrilled to welcome you to our upcoming webinar “Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy" that promises to be a pivotal event under the Special Issue “Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy”.

In this engaging webinar, we will shed light on the critical role of the NRF-2 transcription factor (nuclear factor erythroid 2-related factor 2) in modulating inflammatory diseases and how natural compounds offer valuable insights for research and development of effective therapies.

Join us as we delve into the latest discoveries and insights surrounding NRF-2, a pivotal protein in stress response and inflammation regulation, and explore the potential implications for therapeutic interventions.

Register now to secure your spot!

Date: 28 June 2024 at 03:00 p.m. CEST | 09:00 a.m. EDT | 09:00 p.m. CST Asia
Webinar ID: 854 8025 5074
Webinar link: https://sciforum.net/event/Topics-24

After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.

Register now for free!

Webinar Chair and Keynote Speakers:

• Marisa Freitas, LAQV-REQUIMTE, Associate Laboratory for Green Chemistry, Faculty of Pharmacy of University of Porto, Portugal;
• Paulo Matafome, Instituto Politécnico de Coimbra, Escola Superior de Tecnologia da Saúde de Coimbra, Portugal;
• Alexandre Borbely, Institute of Biological and Health Sciences, Federal University of Alagoas, Brazil;
• Prof. Maria Teresa Cruz, Faculty of Pharmacy, University of Coimbra, Portugal.

Relevant Special Issue:
“Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy, 2nd Edition”
Guest Editors: Eduarda Fernandes, Marisa Freitas and Ana Teresa Rufino
Deadline for manuscript submissions: 20 July 2024 

MDPI is pleased to announce the inclusion of 237 journals in the 2024 release of the Journal Citation Reports (JCR) and share the key results (see above).

This year, journals covered in the Emerging Sources Citation Index (ESCI) received category ranks together with journals in the Science Citation Index Expanded (SCIE) and Social Sciences Citation Index (SSCI). Overall, 139 MDPI journals indexed in ESCI are included in the new unified rankings for the first time.

Enhanced Comparability of Data

According to Clarivate, "the creation of unified category rankings [provides] a simpler and more complete category view for the evaluation of journal performance. [...] The category-first approach simplifies journal performance assessment with a holistic view of all journals in each subject category."

We are thrilled to announce that 72% of our ranked MDPI journals (171 of 237) are above average, in Q1 or Q2. Twenty-nine of our journals received their first Impact Factor this year, accounting for more than 5% of the journals accepted into the Web of Science last year.

MDPI Journals Ranked in JCR

The following data includes all MDPI journals indexed in SCIE, SSCI, ESCI and AHCI.

Source: 2023 Journal Impact Factors, Journal Citation Reports ^TM (Clarivate, 2024)

About MDPI

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 professional, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 440 fully open access titles.

1. “Ionotropic Gelation and Chemical Crosslinking as Methods for Fabrication of Modified-Release Gellan Gum-Based Drug Delivery Systems”
by Piotr Gadziński, Anna Froelich, Barbara Jadach, Monika Wojtyłko, Adam Tatarek, Antoni Białek, Julia Krysztofiak, Michał Gackowski, Filip Otto and Tomasz Osmałek
Pharmaceutics 2023, 15(1), 108; https://doi.org/10.3390/pharmaceutics15010108
Available online: https://www.mdpi.com/1999-4923/15/1/108

2. “Tri-Layer Core–Shell Fibers from Coaxial Electrospinning for a Modified Release of Metronidazole”
by Ying Wang, Lin Liu, Yuanjie Zhu, Liangzhe Wang, Deng-Guang Yu, and Li-ying Liu
Pharmaceutics 2023, 15(11), 561; https://doi.org/10.3390/pharmaceutics15112561
Available online: https://www.mdpi.com/1999-4923/15/11/2561

3. “Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations”
by Frédéric Frézard, Marta M. G. Aguiar, Lucas A. M. Ferreira, Guilherme S. Ramos, Thais T. Santos, Gabriel S. M. Borges, Virgínia M. R. Vallejos and Helane L. O. De Morais
Pharmaceutics 2023, 15(1), 99; https://doi.org/10.3390/pharmaceutics15010099
Available online: https://www.mdpi.com/1999-4923/15/1/99

4. “GelMA, Click-Chemistry Gelatin and Bioprinted Polyethylene Glycol-Based Hydrogels as 3D Ex Vivo Drug Testing Platforms for Patient-Derived Breast Cancer Organoids”
by Nathalie Bock, Farzaneh Forouz, Luke Hipwood, Julien Clegg, Penny Jeffery, Madeline Gough, Tirsa van Wyngaard, Christopher Pyke, Mark N. Adams, Laura J. Bray et al.
Pharmaceutics 2023, 15(1), 261; https://doi.org/10.3390/pharmaceutics15010261
Available online: https://www.mdpi.com/1999-4923/15/1/261

5. “A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future”
by Emily Holz, Martine Darwish, Devin B. Tesar and Whitney Shatz-Binder
Pharmaceutics 2023, 15(2), 600; https://doi.org/10.3390/pharmaceutics15020600
Available online: https://www.mdpi.com/1999-4923/15/2/600

6. “Antibacterial Activity of Zinc Oxide Nanoparticles Loaded with Essential Oils”
by Ludmila Motelica, Bogdan-Stefan Vasile, Anton Ficai, Adrian-Vasile Surdu, Denisa Ficai, Ovidiu-Cristian Oprea, Ecaterina Andronescu, Gabriel Mustățea, Elena Loredana Ungureanu and Alina Alexandra Dobre
Pharmaceutics 2023, 15(10), 2470; https://doi.org/10.3390/pharmaceutics15102470
Available online: https://www.mdpi.com/1999-4923/15/10/2470

7. “Formulation and Characterisation of Carbamazepine Orodispersible 3D-Printed Mini-Tablets for Paediatric Use”
by Jiayu Hu, Rawan Fitaihi, Shorooq Abukhamees and Hend E. Abdelhakim
Pharmaceutics 2023, 15(1), 250; https://doi.org/10.3390/pharmaceutics15010250
Available online: https://www.mdpi.com/1999-4923/15/1/250

8. “Impact of Tablet Size and Shape on the Swallowability in Older Adults”
by Henriette Hummler, Cordula Stillhart, Lisa Meilicke, Michael Grimm, Elischa Krause, Marwan Mannaa, Maik Gollasch, Werner Weitschies and Susanne Page
Pharmaceutics 2023, 15(4), 1042; https://doi.org/10.3390/pharmaceutics15041042
Available online: https://www.mdpi.com/1999-4923/15/4/1042

9. “Evaluating the Skin Interactions and Permeation of Alginate/Fucoidan Hydrogels Per Se and Associated with Different Essential Oils”
by Ana Isabel Barbosa, Sofia A. Costa Lima, Ibraheem Yousef and Salette Reis
Pharmaceutics 2023, 15(1), 190; https://doi.org/10.3390/pharmaceutics15010190
Available online: https://www.mdpi.com/1999-4923/15/1/190

10. “Recent Advances in Co-Former Screening and Formation Prediction of Multicomponent Solid Forms of Low Molecular Weight Drugs”
by Yuehua Deng, Shiyuan Liu, Yanbin Jiang, Inês C. B. Martins and Thomas Rades
Pharmaceutics 2023, 15(9), 2174; https://doi.org/10.3390/pharmaceutics15092174
Available online: https://www.mdpi.com/1999-4923/15/9/2174

We are pleased to inform you that Pharmaceutics (ISSN: 1999-4923) has received a heightened CiteScore of 7.9.

Pharmaceutics’ CiteScore ranks 32 among 183 titles (Q1) in the “Pharmaceutical Science” category.

CiteScore provides transparent metrics that enable well-informed publishing strategies, library collection development, and the benchmarking of journal performance. It is now a standard citation metric alongside SNIP and SJR that gives an up-to-date view of a journal’s impact. The 2023 CiteScore provides an assessment of the scientific influence of journals in the 2020 to 2023 period.

This result is a reflection of the excellent performance, support, and dedication of all journal editors, reviewers, authors, and readers.

For more journal statistics, please visit https://www.mdpi.com/journal/pharmaceutics/stats.

Thank you to everyone who has contributed to the journal.

Pharmaceutics Editorial Office

On UNESCO’s 2024 Oceans Day, MDPI encourages the scientific community to increase the accessibility of ocean research to accelerate ocean conservation.

Basel, Switzerland, June 7, 2024: MDPI, a leading open access (OA) publisher, is proud to announce its active support for World Oceans Day 2024, celebrated under UNESCO’s Ocean Decade framework. MDPI’s CEO, Stefan Tochev hopes that “the latest ocean research can be made freely accessible to help empower scientists and communities at large to save our oceans,” under UNESCO’s Ocean Decade until 2030.

Open Access: A Catalyst for Ocean Action

MDPI’s presence at the UNESCO Ocean Decade Conference 2024 highlights our unwavering commitment to using OA to advance ocean science, support research communities, and promote sustainable ocean management.

"Our involvement in the UNESCO Ocean Decade Conference underscores MDPI's commitment to the underfunded Ocean SDG. By promoting OA to scientific articles and books on SDGs, we aim to inspire critical actions," said Tochev. "Our initiatives, like the World Sustainability Award and Emerging Sustainability Award, further demonstrate our dedication to advancing sustainability.”

Showcasing MDPI’s Contributions to Ocean Research

Over the past three years, MDPI has published 30,000 papers focused on ocean research and related topics. Key MDPI journals contributing to this body of work include:

• Journal of Marine Science and Engineering (4.9k papers)
• Remote Sensing (2.6k papers)
• Sustainability (2k papers)
• International Journal of Molecular Sciences (IJMS) (1.7k papers)
• Marine Drugs (1.5k papers)
• Water (1.5k papers)

These publications highlight MDPI’s contributions to ocean science, reinforcing our role in the broader sustainability agenda by promoting blue innovation and economy.

Additionally, MDPI has launched Oceans, an international, peer-reviewed forum specifically aimed at publishing studies related to all branches of oceanography with an emphasis on the functioning of the ocean and the sustainable use of its resources and ecosystem services.

Affirming MDPI’s Commitment to Ocean Science

MDPI’s commitment to OA is pivotal in addressing critical global challenges, from climate change to ocean sustainability. Our efforts resonate with Outcome 4 of the UNESCO Ocean Decade action roadmap: an accessible ocean with open and equitable access to data, information, technology, and innovation. By aligning with UNESCO’s goals, MDPI continues to contribute to shaping a sustainable future for our oceans, reinforcing our position as a forward-thinking publisher dedicated to environmental stewardship and scientific excellence.

For more information, contact Rui Duarte at [email protected] or +41764313242.

About MDPI

95% of authors rate MDPI’s publication process as excellent or good, setting a new benchmark in scientific publishing – reveals 2023 Annual Report. 

Basel, Switzerland, June 4, 2024: MDPI, the leading open access (OA) publisher, proudly announces the release of its 2023 Annual Report, detailing remarkable achievements and reaffirming its leadership in advancing OA publishing. In 2023, MDPI received 655,065 submissions, of which 285,244 articles were published. The company now commands a 17% market share in gold open access articles, with a median publication time of six weeks.

Stefan Tochev, MDPI's CEO, stated, "As a pioneer in open access publishing, MDPI has long been a game-changer in the scholarly community, serving millions of authors around the world to ensure the latest research is freely available. Reflecting on our incredible journey at MDPI, 2023 has been marked by growth in paper submissions, ambitious projects and initiatives aimed at improving our internal processes and delivering top-notch services to our scientists."

MDPI's 2023 Annual Report highlights several key achievements:

• 17% market share in gold open access articles across all disciplines.
• Record satisfaction rates: 95% of authors, 82% of reviewers, and 85% of guest editors.
• Enhanced editorial standards and feedback processes.
• Increased reach and impact with 54 new MDPI journal inclusions in Scopus, 29 in Web of Science, and 77 in DOAJ.

MDPI’s unwavering commitment to advancing OA has transformed the landscape of scholarly publishing, making high-quality research freely accessible to the global scientific community. The continuous improvement in our editorial standards and feedback processes underscores MDPI’s dedication to ensuring academic integrity and excellence.

Global Reach and Collaboration

MDPI’s global footprint continues to expand, with authors from diverse regions: 37% from Asia/Pacific, 36% from Europe, 15% from the Americas, and 12% from other parts of the world. The company’s fully OA platform attracted nearly 14 million monthly visitors in 2023, reflecting its widespread influence in the scientific community.

Commitment to Partnerships

With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services. The introduction of a transparent flat-fee model highlights MDPI's ongoing efforts to enhance affordability and support to the academic community. For more details read our 2023 Annual Report.

For more information, contact Rui Duarte at [email protected] or +41764313242.

About MDPI

The ESMO Congress is a globally influential oncology platform that unites clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO 2024 will disseminate the latest cutting-edge data, providing high-quality education and excellent networking opportunities for oncologists and other stakeholders on an international level.

The following MDPI journals will be represented:

• Cancers;
• JCM;
• Healthcare;
• Pharmaceutics;
• Applied Biosciences;
• Dermatopathology;
• Onco;
• Biomedicines;
• Cells;
• Diagnostics;
• Current Oncology;
• Immuno;
• Hemato;
• Gastrointestinal Disorders;
• Biologics;
• Biomolecules;
• Clinics and Practice;
• Medical Sciences.

If you are participating in this conference, please feel free to engage with us online prior to attendance. Our delegates look forward to meeting you in person at booth #P627 and answering any questions you may have. For more information regarding the conference, please visit the following link: https://www.esmo.org/meeting-calendar/esmo-congress-2024.

We are pleased to announce that Prof. Dr. Wei Wu has been appointed Section Editor-in-Chief of the “Nanomedicine and Nanotechnology” Section in Pharmaceutics (ISSN: 1999-4923). With his extensive background in scientific research and publishing, he will bring a wealth of knowledge and expertise to this prestigious role.

Prof. Dr. Wu is a professor at the Fudan University School of Pharmacy, Shanghai, China, and the director of the Fudan-Ruixing Joint Laboratories of Pharmaceutical Nanotechnology. He was the Vice Dean of his school and Deputy Director of the Institute of Pharmacy. He is currently the Vice President of Pharmaceutics and Particle Design Chapter of the China Particuology Society and the Vice President of Pharmaceutical Dosage Forms of the Traditional Chinese Medicine Committee of the World Union of TCM. His expertise is in nanomedicine, biopharmaceutics, and pharmaceutical nanotechnology. He has published more than 300 peer-reviewed publications in prestigious journals on pharmaceutics, drug delivery, and nanomedicines. A full list of his publications can be found here.

Prof. Dr. Wu and coworkers developed new types of NIR-I and NIR-II fluorophores with absolute aggregation-caused quenching (ACQ) properties for accurate bioimaging and quantification of drug nanocarriers. His group established the basic concepts and methodologies regarding nanocarrier analysis and particokinetics. He has also been among the World's Top 2% Scientists (annual and career) for several consecutive years in pharmacology and toxicology, according to the list created by researchers from Stanford University. He has also been awarded for his research and academic excellence, including New Century Excellent Talent of Ministry of Education, Shanghai Excellent Discipline Leaders, Shanghai Twilight Scholars, and Distinguished Lectureship by the Nagai Foundation Tokyo.

The following is a short Q&A with Prof. Dr. Wei Wu, who shared his vision for the journal with us, as well as his views on the research area and open access publishing:

1. What appealed to you about the journal that made you want to become its Section Editor-in-Chief?
Pharmaceutics has established a platform for communication and dissemination of knowledge within and outside of the pharmaceutics and drug delivery community. In the past, I benefited significantly from Pharmaceutics as an author, and I am satisfied for contributing to the scientific community in the role of a reviewer or an Editorial Board Member. To be a Section Editor-in-Chief, I regard it as a great opportunity to better serve the pharmaceutics and drug delivery community.

2. What are your plans and vision for the Section and the journal?
As Pharmaceutics has established its place and influence in the cross-field of pharmaceutics, drug delivery, and nanomedicines, my vision for it is steady growth, serving the scientific community with more high-quality contributions, more open access publications, and continuously increasing impact. In view of the booming research trends in nanomedicine and nanotechnology, my vision is to continuously lead the Sections and make growing contributions to the development of Pharmaceutics.

3. What does the future of this field of research look like?
Against the backdrop of the rapid development of innovative drugs and delivery systems, the field of pharmaceutics has experienced continuous growth in recent decades, and this trend will surely continue because of the demands of precision medicine for delicately orchestrated delivery strategies and delivery systems. That said, all endeavors in the discovery stages will only lead to the prosperity of pharmaceutics. Nonetheless, in the future, pharmaceutics may welcome new active ingredients spanning from small molecules to biomacromolecules and to new combinations and compounds with multiple components, which may challenge and push forward the development of theories, mindsets, and technologies in pharmaceutics and drug delivery.

4. What do you think of the development of open access in the publishing field?
Open access publication definitely benefits the scientific community by offering free access. However, excessive commercialization by compromising article quality would stymie the development of open access scientific publishing. By adhering to strict peer review standards, open access publishing may flourish, switching to a virtuous circle.

We warmly welcome Prof. Dr. Wei Wu as the new Section Editor-in-Chief and we look forward to him leading Pharmaceutics to many more milestones.

1. “3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals”
by Dolores R. Serrano, Aytug Kara, Iván Yuste, Francis C. Luciano, Baris Ongoren, Brayan J. Anaya, Gracia Molina, Laura Diez, Bianca I. Ramirez, Irving O. Ramirez et al.
Pharmaceutics 2023, 15(2), 313; https://doi.org/10.3390/pharmaceutics15020313
Available online: https://www.mdpi.com/1999-4923/15/2/313

2. “Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery”
by Van-An Duong, Thi-Thao-Linh Nguyen and Han-Joo Maeng
Pharmaceutics 2023, 15(1), 207; https://doi.org/10.3390/pharmaceutics15010207
Available online: https://www.mdpi.com/1999-4923/15/1/207

3. “Electrospinning of Potential Medical Devices (Wound Dressings, Tissue Engineering Scaffolds, Face Masks) and Their Regulatory Approach”
by Luca Éva Uhljar and Rita Ambrus
Pharmaceutics 2023, 15(2), 417; https://doi.org/10.3390/pharmaceutics15020417
Available online: https://www.mdpi.com/1999-4923/15/2/417

4. “Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics”
by Yaqeen Nadheer Al Badri , Cheng Shu Chaw and Amal Ali Elkordy
Pharmaceutics 2023, 15(1), 294; https://doi.org/10.3390/pharmaceutics15010294
Available online: https://www.mdpi.com/1999-4923/15/1/294

5. “Fabrication of Gastro-Floating Famotidine Tablets: Hydroxypropyl Methylcellulose-Based Semisolid Extrusion 3D Printing”
by Hyun Seok Yang and Dong Wuk Kim
Pharmaceutics 2023, 15(2), 316; https://doi.org/10.3390/pharmaceutics15020316
Available online: https://www.mdpi.com/1999-4923/15/2/316

6. “3D-Printed Fast-Dissolving Oral Dosage Forms via Fused Deposition Modeling Based on Sugar Alcohol and Poly(Vinyl Alcohol)—Preparation, Drug Release Studies and In Vivo Oral Absorption”
by Sorato Ikeda, Masanori Kobayashi, Soken Aoki, Takayuki Terukina, Takanori Kanazawa, Hiroyuki Kojima and Hiromu Kondo
Pharmaceutics 2023, 15(2), 395; https://doi.org/10.3390/pharmaceutics15020395
Available online: https://www.mdpi.com/1999-4923/15/2/395

7. “Evaluation of a Medical Grade Thermoplastic Polyurethane for the Manufacture of an Implantable Medical Device: The Impact of FDM 3D-Printing and Gamma Sterilization”
by Marie-Stella M’Bengue, Thomas Mesnard, Feng Chai, Mickaël Maton, Valérie Gaucher, Nicolas Tabary, Maria-José García-Fernandez, Jonathan Sobocinski, Bernard Martel and Nicolas Blanchemain
Pharmaceutics 2023, 15(2), 456; https://doi.org/10.3390/pharmaceutics15020456
Available online: https://www.mdpi.com/1999-4923/15/2/456

8. “Development and Optimisation of Inhalable EGCG Nano-Liposomes as a Potential Treatment for Pulmonary Arterial Hypertension by Implementation of the Design of Experiments Approach”
by Fatma Haddad, Nura Mohammed, R. C. Gopalan, Yousef Al Ayoub, Md Talat Nasim and K. H. Assi
Pharmaceutics 2023, 15(2), 539; https://doi.org/10.3390/pharmaceutics15020539
Available online: https://www.mdpi.com/1999-4923/15/2/539

1. “Electrosprayed Core (Cellulose Acetate)–Shell (Polyvinylpyrrolidone) Nanoparticles for Smart Acetaminophen Delivery”
by Lin Xu, Hua He, Yutong Du, Shengwei Zhang, Deng-Guang Yu and Ping Liu
Pharmaceutics 2023, 15(9), 2314; https://doi.org/10.3390/pharmaceutics15092314
Available online: https://www.mdpi.com/1999-4923/15/9/2314

2. “ZnO@ZIF-8 Nanoparticles as Nanocarrier of Ciprofloxacin for Antimicrobial Activity”
by Bruno Altran Costa, Marina Paiva Abuçafy, Thúlio Wliandon Lemos Barbosa, Bruna Lallo da Silva, Rafael Bianchini Fulindi, Guilherme Isquibola, Paulo Inácio da Costa and Leila Aparecida Chiavacci
Pharmaceutics 2023, 15(1), 259; https://doi.org/10.3390/pharmaceutics15010259
Available online: https://www.mdpi.com/1999-4923/15/1/259

3. “Liposomal Iron Oxide Nanoparticles Loaded with Doxorubicin for Combined Chemo-Photothermal Cancer Therapy”
by Taehoon Park, Reeju Amatya, Kyoung Ah Min and Meong Cheol Shin
Pharmaceutics 2023, 15(1), 292; https://doi.org/10.3390/pharmaceutics15010292
Available online: https://www.mdpi.com/1999-4923/15/1/292

4. “Increasing Bioavailability of Trans-Ferulic Acid by Encapsulation in Functionalized Mesoporous Silica”
by Gabriela Petrișor, Ludmila Motelica, Denisa Ficai, Cornelia-Ioana Ilie, Roxana Doina Trușcǎ, Vasile-Adrian Surdu, Ovidiu-Cristian Oprea, Andreea-Luiza Mȋrț, Gabriel Vasilievici, Augustin Semenescu et al.
Pharmaceutics 2023, 15(2), 660; https://doi.org/10.3390/pharmaceutics15020660
Available online: https://www.mdpi.com/1999-4923/15/2/660

5. “Effect of the Size and Shape of Dendronized Iron Oxide Nanoparticles Bearing a Targeting Ligand on MRI, Magnetic Hyperthermia, and Photothermia Properties—From Suspension to In Vitro Studies”
by Barbara Freis, Maria De Los Angeles Ramirez, Céline Kiefer, Sébastien Harlepp, Cristian Iacovita, Céline Henoumont, Christine Affolter-Zbaraszczuk, Florent Meyer, Damien Mertz, Anne Boos et al.
Pharmaceutics 2023, 15(4), 1104; https://doi.org/10.3390/pharmaceutics15041104
Available online: https://www.mdpi.com/1999-4923/15/4/1104

6. “Antimicrobial Nano-Zinc Oxide Biocomposites for Wound Healing Applications: A Review”
by Paolo Pino, Francesca Bosco, Chiara Mollea and Barbara Onida
Pharmaceutics 2023, 15(3), 970; https://doi.org/10.3390/pharmaceutics15030970
Available online: https://www.mdpi.com/1999-4923/15/3/970

7. “Cationic Polymers as Transfection Reagents for Nucleic Acid Delivery”
by Xiaomeng Cai, Rui Dou, Chen Guo, Jiaruo Tang, Xiajuan Li, Jun Chen and Jiayu Zhang
Pharmaceutics 2023, 15(5), 1502; https://doi.org/10.3390/pharmaceutics15051502
Available online: https://www.mdpi.com/1999-4923/15/5/1502

8. “Superparamagnetic Iron Oxide Nanoparticles (SPION): From Fundamentals to State-of-the-Art Innovative Applications for Cancer Therapy”
by Thomas Vangijzegem, Valentin Lecomte, Indiana Ternad, Levy Van Leuven, Robert N. Muller, Dimitri Stanicki and Sophie Laurent
Pharmaceutics 2023, 15(1), 236; https://doi.org/10.3390/pharmaceutics15010236
Available online: https://www.mdpi.com/1999-4923/15/1/236

9. “Chitosan-Based Nanoparticles with Optimized Parameters for Targeted Delivery of a Specific Anticancer Drug—A Comprehensive Review”
by Joanna Kurczewska
Pharmaceutics 2023, 15(2), 503; https://doi.org/10.3390/pharmaceutics15020503
Available online: https://www.mdpi.com/1999-4923/15/2/503

10. “Carbon Dots: Opportunities and Challenges in Cancer Therapy”
by Tanima Bhattacharya, Gye Hwa Shin and Jun Tae Kim
Pharmaceutics 2023, 15(3), 1981; https://doi.org/10.3390/pharmaceutics13111981
Available online: https://www.mdpi.com/1999-4923/13/11/1981

1. “Advances in Oral Drug Delivery Systems: Challenges and Opportunities”
by Jie Lou, Hongli Duan, Qin Qin, Zhipeng Teng, Fengxu Gan, Xiaofang Zhou and Xing Zhou
Pharmaceutics 2023, 15(2), 484; https://doi.org/10.3390/pharmaceutics15020484
Available online: https://www.mdpi.com/1999-4923/15/2/484

2. “Drug Delivery Systems in Regenerative Medicine: An Updated Review”
by Alaa Mansour, Maya Romani, Anirudh Balakrishna Acharya, Betul Rahman, Elise Verron and Zahi Badran
Pharmaceutics 2023, 15(2), 695; https://doi.org/10.3390/pharmaceutics15020695
Available online: https://www.mdpi.com/1999-4923/15/2/695

3. “Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy”
by Ana Camila Marques, Paulo C. Costa, Sérgia Velho and Maria Helena Amaral
Pharmaceutics 2023, 15(1), 216; https://doi.org/10.3390/pharmaceutics15010216
Available online: https://www.mdpi.com/1999-4923/15/1/216

4. “Current Trends in Gelatin-Based Drug Delivery Systems”
by Francesca Milano, Annalia Masi, Marta Madaghiele, Alessandro Sannino, Luca Salvatore and Nunzia Gallo
Pharmaceutics 2023, 15(5), 1499; https://doi.org/10.3390/pharmaceutics15051499
Available online: https://www.mdpi.com/1999-4923/15/5/1499

5. “Rapidly Dissolving Microneedles for the Delivery of Steroid-Loaded Nanoparticles Intended for the Treatment of Inflammatory Skin Diseases”
by Hala Dawud and Aiman Abu Ammar
Pharmaceutics 2023, 15(2), 526; https://doi.org/10.3390/pharmaceutics15020526
Available online: https://www.mdpi.com/1999-4923/15/2/526

6. “Metal–Organic Frameworks and Their Biodegradable Composites for Controlled Delivery of Antimicrobial Drugs”
by Tayah C. Livesey, Lila A. M. Mahmoud, Maria G. Katsikogianni and Sanjit Nayak
Pharmaceutics 2023, 15(1), 274; https://doi.org/10.3390/pharmaceutics15010274
Available online: https://www.mdpi.com/1999-4923/15/1/274

7. “Controlled Drug Release from Nanoengineered Polysaccharides”
by Ilker S. Bayer
Pharmaceutics 2023, 15(5), 1364; https://doi.org/10.3390/pharmaceutics15051364
Available online: https://www.mdpi.com/1999-4923/15/5/1364

8. “Plant-Derived Extracellular Vesicles as a Delivery Platform for RNA-Based Vaccine: Feasibility Study of an Oral and Intranasal SARS-CoV-2 Vaccine”
by Margherita A. C. Pomatto, Chiara Gai, Federica Negro, Lucia Massari, Maria Chiara Deregibus, Cristina Grange, Francesco Giuseppe De Rosa and Giovanni Camussi
Pharmaceutics 2023, 15(3), 974; https://doi.org/10.3390/pharmaceutics15030974
Available online: https://www.mdpi.com/1999-4923/15/3/974

9. “Biodistribution of Intratracheal, Intranasal, and Intravenous Injections of Human Mesenchymal Stromal Cell-Derived Extracellular Vesicles in a Mouse Model for Drug Delivery Studies”
by Anna Maria Tolomeo, Gaia Zuccolotto, Ricardo Malvicini, Giada De Lazzari, Alessandro Penna, Chiara Franco, Federico Caicci, Fabio Magarotto, Santina Quarta, Michela Pozzobon et al.
Pharmaceutics 2023, 15(2), 548; https://doi.org/10.3390/pharmaceutics15020548
Available online: https://www.mdpi.com/1999-4923/15/2/548

10. “Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy”
by Christoph Wilhelmy, Isabell Sofia Keil, Lukas Uebbing, Martin A. Schroer, Daniel Franke, Thomas Nawroth, Matthias Barz, Ugur Sahin, Heinrich Haas, Mustafa Diken et al.
Pharmaceutics 2023, 15(8), 2068; https://doi.org/10.3390/pharmaceutics15082068
Available online: https://www.mdpi.com/1999-4923/15/8/2068

11. “Low-Level Laser Treatment Induces the Blood-Brain Barrier Opening and the Brain Drainage System Activation: Delivery of Liposomes into Mouse Glioblastoma”
by Oxana Semyachkina-Glushkovskaya, Denis Bragin, Olga Bragina, Sergey Socolovski, Alexander Shirokov, Ivan Fedosov, Vasily Ageev, Inna Blokhina, Alexander Dubrovsky, Valeria Telnova et al.
Pharmaceutics 2023, 15(2), 567; https://doi.org/10.3390/pharmaceutics15020567
Available online: https://www.mdpi.com/1999-4923/15/2/567

12. “Amorphous Pterostilbene Delivery Systems Preparation—Innovative Approach to Preparation Optimization”
by Natalia Rosiak, Ewa Tykarska and Judyta Cielecka-Piontek
Pharmaceutics 2023, 15(4), 1231; https://doi.org/10.3390/pharmaceutics15041231
Available online: https://www.mdpi.com/1999-4923/15/4/1231

We are pleased to announce MDPI’s Transfer Service.

This service provides a convenient method of transferring your manuscript file, along with any reviewer comments, to another journal within our publishing portfolio.

We are committed to helping authors find the right home for their research, and we will provide authors with guidance and technical support through all stages of the transfer process. Authors will be able to choose to transfer in the following two situations:

1. Select alternative journals on submission.

2. Authors are encouraged to transfer manuscripts to other MDPI journals.

More details about the Transfer Service can be found at the following link:

https://www.mdpi.com/authors/transfer-service

We are pleased to announce that Prof. Dr. Francisco Javier Otero-Espinar has been appointed Section Editor-in-Chief of the “Drug Delivery and Controlled Release” Section in Pharmaceutics (ISSN: 1999-4923). With an extensive background in scientific research and publishing, he will bring a wealth of knowledge and expertise to this prestigious role.

Prof. Dr. Francisco Javier Otero-Espinar is a pharmacist and a pharmaceutical scientist at the Faculty of Pharmacy, at the University of Santiago de Compostela, Spain. He is a member of the Institute of Materials (iMATUS) and the Health Research Institute (IDIS) of Santiago de Compostela. His scientific endeavors primarily focus on biopharmaceutics, pharmacokinetics, and pharmaceutical technology. He specializes in the development of drug-controlled release systems for various routes of administration, including oral, parenteral, dermal, ophthalmic, and others. Additionally, he works on the development of release systems for biological drugs and their physicochemical, biopharmaceutical, and pharmacokinetic characterization.

He is a Fellow of the Spanish Society of Industrial and Galenical Pharmacy (SEFIG), where he served as a Secretary and later, President. Additionally, he is a member of the Spanish–Portuguese CRS local chapter and various networks associated with controlled release and nanomedicine. Formerly, he has served as the Dean of the Faculty of Pharmacy in Santiago de Compostela and, presently, coordinates the research group PARAQUASIL.

Throughout his career, he has actively engaged in projects and contracts with the pharmaceutical industry, accumulating substantial experience in technology transfer and knowledge dissemination to the public and private sector.

The following is a short Q&A with Prof. Dr. Francisco Javier Otero-Espinar, who shared his vision for the journal with us, as well as his views on the research area and open access publishing:

1. What appealed to you about the journal that made you want to become its Section Editor-in-Chief?
I have been involved in Pharmaceutics for several years, serving as a member of its Editorial Board. Pharmaceutics aligns closely with my scientific interests, and I have consistently encountered highly interesting and high-quality articles and papers that have supported my research endeavors.

2. What are your plans and vision for the journal?
I believe that Pharmaceutics should persist in publishing high-quality articles concerning pharmaceutical development, biopharmaceutics, pharmaceutical technology, and pharmacology. Specifically, the advancement of novel dosage forms and controlled drug release mechanisms should be prioritized. To this end, I intend to collaborate in attracting top scientists working in these fields to consider Pharmaceutics as a prime outlet for disseminating their research.

3. What does the future of this field of research look like?
New drug discovery is becoming progressively more expensive, thus highlighting the significant potential of specialized controlled release systems to enhance current treatments. Conversely, the emergence of new biological drugs has fundamentally altered the principles governing the design, formulation, and regulation of delivery systems for these molecules. This represents an emerging field necessitating a fresh perspective in research methodologies.

4. What do you think of the development of open access literature in the publishing field?
Open access publications have significantly broadened access to information for numerous scientists and laboratories, thereby facilitating the dissemination of knowledge. However, a challenge arises for scientists and organizations lacking the financial resources to afford open access publication fees. In such cases, the initiatives of certain journals to waive or reduce publication costs are greatly valued. It is also very important to maintain a high ethical standard of open access publications to ensure the quality and interest of researchers in this type of publication model.

We warmly welcome Prof. Dr. Francisco Javier Otero-Espinar as the Section Editor-in-Chief of “Drug Delivery and Controlled Release” and look forward to his contribution to the continued success of the journal.

We are pleased to announce that Prof. Dr. Dimitrios A. Lamprou has been appointed Section Editor-in-Chief of the Section “Physical Pharmacy and Formulation” in Pharmaceutics (ISSN: 1999-4923). With his extensive background in scientific research and publishing, he will bring a wealth of knowledge and expertise to this prestigious role.

Prof. Dr. Dimitrios A. Lamprou (Ph.D., MBA) is the Chair of Biofabrication and Advanced Manufacturing, and Director of MSc Industrial Pharmaceutics at Queen's University Belfast, UK. He is also the Chair of the United Kingdom and Ireland Controlled Release Society (UKICRS). Moreover, he is an expert in emerging biopharmaceutical and pharmaceutical technologies, with over 160 peer-reviewed publications and over 450 conference abstracts, and has delivered over 180 invited talks at institutions and conferences across the world.

Prof. Dr. Lamprou is a recognized world leader in 3D printing and microfluidics, with PubMed-based algorithms placing him in the top 0.1% of scholars writing about 3D printing and in the top 0.07% of scholars writing about microfluidics over the past 10 years. He has also been named in Stanford University's list of the World's Top 2% Scientists for several consecutive years thanks to his research on pharmaceutics and biomedical engineering. His research and academic leadership have been recognized through a range of awards, including the Royal Pharmaceutical Society (RPS) Science Award, the Scottish Universities Life Sciences Alliance (SULSA) Leaders Scheme Award, and Doctor Honoris Causa Award by Semmelweis University (Hungary). More info can be found at www.emergingtechnologieslab.com.

The following is a short Q&A with Prof. Dr. Dimitrios A. Lamprou, who shared his vision for the journal with us, as well as his views on the research area and open access publishing:

1. What appealed to you about the journal that made you want to become its Section Editor-in-Chief?
I am very familiar with the journal as I have been serving as an editor of Pharmaceutics for many years, checking 50+ papers, editing 10+ Special Issues, and organizing two successful webinars. With this appointment, I will be able to further support the journal, weed out low-quality contributions, guarantee the caliber of the articles that are published, and, at the same time, boost the topic.

2. What are your plans and vision for the journal?
“Physical Pharmacy and Formulation” examines the physicochemical properties of liquid and semi-solid pharmaceutical dosage forms to deliver an active pharmaceutical ingredient (API), and the research on the topic is crucial in drug discovery research for new molecules and excipient development. The topic is also very important for the development of safer drug delivery systems (DDSs) for future medicines. The main vision of this open access section is to make this important research more visual to researchers in the field by bringing fundamental and advanced research to them, supporting the development of advanced DDSs.

3. What does the future of this field of research look like?
This field was always very important and a hot topic. To keep the rise in research with coherent and strong manuscripts, we must make sure that new Special Issues are introduced with improved standards and selectivity. The topic to be developed needs high-quality manuscripts, and to achieve this there need to be strict regulations and higher standards.

4. What do you think of the development of open access literature in the publishing field?
Currently, the majority of traditionally subscription-based journals offer open access as an option, which is great since research must be available to everyone. For journals that are offering only open access, there needs to be a focus on the quality of the manuscripts. There are so many open access journals these days, with more advertised every day; therefore, one needs to be continuously creative and strictly monitor and uphold publishing ethics.

We warmly welcome Prof. Dr. Dimitrios A. Lamprou as the Section Editor-in-Chief of “Physical Pharmacy and Formulation” and look forward to his contribution to the continued success of the journal.

In acknowledgment of the groundbreaking achievements of Professor Tu Youyou, the Nobel laureate credited with the discovery of artemisinin, MDPI is proud to announce the Tu Youyou Award. This award, inaugurated in 2016, seeks to honor scholars who excel in the fields of natural products chemistry and medicinal chemistry.

Prize:

• CHF 100,000 in total (If there is more than one winner, the prize will be divided equally amongst the winners);
• An award medal for each winner.

Who should be nominated?

• Scientists with outstanding achievements and contributions in the fields of natural products chemistry and medicinal chemistry.

Who can submit a nomination?

• Academic research institutes
• Universities
• Academic societies

Any personal nominations are not accepted.

How do I submit a nomination?
Candidates’ institutional affiliations need to submit their nominations for final candidates to the Tu Youyou Award Team directly by email after internal screening, and each institution can only nominate a maximum of two candidates for each edition of the Tu Youyou Award. Please note that the nominations cannot be modified once they are submitted and confirmed by the Tu Youyou Award Team.

Required nomination materials:
Nomination Form (Download)

Schedule:
Nomination deadline: 31 December 2024;
Winner announcement: 30 April 2025.

Contact:
Tu Youyou Award Team ([email protected])

More information can be found on the Tu Youyou Award official website. For any inquiries, do not hesitate to contact the Tu Youyou Award Team.

MDPI Romania sponsored four events over the month of April, contributing author training sessions to each event.

The NutriSciLabs 2024 conference was held at the Carol Davila University of Medicine and Pharmacy on 12 April 2024. Organized by the Association of Students from the Faculty of Pharmacy Studies, the conference aimed to enhance students’ academic writing and research skills, and bolster their confidence in participating in the academic world. Ioana Paunescu, journal relations specialist for MDPI Romania, led the training session. Paunescu first outlined MDPI’s history and core values, then explained academic writing techniques, ethics, and similarity percentages. The presentation covered the entire editorial process, highlighting the amount of attention paid to details throughout manuscript processing. Paunescu also discussed common errors that authors make while writing, and how to avoid such errors.

On 13 April 2024, the NextGEN 2.0 Student Conference took place at the Babes-Bolyai University of Cluj-Napoca. NextGen Healthcare organized this event with the university’s European Students’ Society to discuss European and international current affairs. MDPI Romania contributed an author training session called Steps of the Publication Process. Irina Codruta Zaharia, journal relations specialist, began the session with a general introduction of MDPI before diving into different article types, different layout formats, possible journals to submit to, the MDPI submission checklist, and the MDPI editorial process. By explaining the fundamentals of writing and publishing academic papers, Zaharia imparted valuable industry knowledge to the curious minds present. Participants were eager to engage with Zaharia in the subsequent Q&A session.

Celebrating its 20th anniversary this year, the International Conference “Students for Students” has long been a gathering place for undergraduate and postgraduate students of all nationalities to present their work and exchange ideas with each other. This year’s conference was held on 18 April 2024, with MDPI Romania contributing an author training session called The World of Open Access. Key speakers included Dr. Norbert Kiss from MDPI Romania and Prof. Dragos Horvath from Strasbourg University. Dr. Kiss discussed the history of open access, differences between open access publishing and traditional publishing, and implications for open access in the future. Attendees expressed keen interest in the subject, approaching Dr. Kiss with questions about academic publishing as well as his career trajectory.

Most recently, on 26 April 2024, MDPI Romania sponsored the National Symposium of Students from Geology and Geophysics Faculties. The AAPG Students Chapter at the Babes-Bolyai University organized this event as an opportunity for geology students from all Romanian universities to present their work and confer with other researchers. Dr. Kiss gave his lecture The World of Open Access at this event as well.

MDPI is thankful to all the participants, speakers, and organizers who attended these events. Through their enthusiasm and dedication, these events were great successes.

MDPI, the leading Open Access (OA) publisher, announced on Monday that it opened its Korean branch office on 29th April 2024. With this addition, MDPI now operates 21 offices in 12 countries worldwide. Claude Seo, with over 20 years of experience in the academic journal publishing industry, including Nature Publishing Group (NPG), has been appointed as the Office Manager of the Seoul office.

With the establishment of a Seoul office, MDPI aims to actively support Korea scientific communities to further promote the publication of OA journals in the region. As of the end of 2023, Korea ranked sixth worldwide in both submissions and publications of MDPI research papers. MDPI is the number one OA publisher in Korea.

Sungkyunkwan University Joins MDPI’s Institutional Open Access Program

In addition, MDPI announced that Sungkyunkwan University joined MDPI’s Institutional Open Access Program (IOAP). This program offers free access to MDPI online submission system for the institutions and APC discounts to affiliated authors. Thirteen major Korean universities, including Sungkyunkwan University, Kyung Hee University, Chung-Ang University and Catholic University of Korea, have adopted IOAP in Korea.

OA aims to break down barriers that have traditionally restricted access to science, ensuring that knowledge is available to all, regardless of financial situation or institutional affiliations. Authors, academia, and scientific communities are rapidly moving toward OA. MDPI has been at the forefront of reshaping the academic publishing landscape, with OA surpassing subscription-based publishing in 2020.

MDPI CEO Visits Seoul, Korea

In March, Stefan Tochev, Chief Executive Officer (CEO) of MDPI, visited Korea and met with various stakeholders including government agencies, research and academic institutions, universities. During his visit, Stefan highlighted that MDPI continues to pave the way for a world where science is accessible to all, supporting a global community of inclusive innovation and collaborative solutions.

Stefan expressed excitement about the new venture, stating, "Today marks a significant milestone for MDPI as we celebrate the opening of our new office in Seoul, Korea. This expansion is more than just an increase in our physical footprint, it is a pivotal step in our ongoing commitment to making scientific knowledge more accessible, participatory, and inclusive across the globe."

Claude Seo, reflecting on his new role, commented, "I am delighted to have been offered this position of trust within MDPI, the no. 1 scholarly OA publisher. As we establish our presence in Korea, we are dedicated to integrating into the local community and contributing to its vibrant culture. Our commitment goes beyond business growth; it is about creating a more informed and innovative society by embracing and promoting diversity within the scientific community.”

For further inquiries, please contact our Seoul office directly.

About MDPI

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.3 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 diligent, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 430 fully OA titles.

Conference: The 48th FEBS Congress
Date: 29 June–3 July 2024
Location: Milan, Italy

MDPI will be attending the 48th FEBS Congress at Booth #30, and we welcome researchers from different backgrounds to visit us and share their latest ideas.

The Italian Society of Biochemistry and Molecular Biology (SIB), founded in 1951, will host the event. The 48th FEBS Congress—“Mining biochemistry for human health and well-being”—welcomes scientists from Europe and other parts of the world.

The 48th FEBS Congress will present a broad-spectrum and ground-breaking scientific program in a fruitful collaboration with FEBS journals and representatives from FEBS Constituent Societies. The SIB and biochemical community are focusing on human health and well-being through molecular and cellular science approaches; this is a key social issue amid ongoing global transitions. Besides presenting the latest and emerging developments in biochemical sciences, the Congress will include dedicated education-oriented sessions, symposia organized by young biochemists, and biochemistry-related economic discussions. Industry representatives will also give presentations on the latest advances in commercial instrumentation.

The following MDPI journals will be represented:

• Biomedicines;
• IJMS;
• JMP;
• Antioxidants;
• Applied Biosciences;
• BioMedInformatics;
• Biomolecules;
• Dietetics;
• Life;
• Medical Sciences;
• Molecules;
• Biology;
• Cancers;
• CIMB;
• Pharmaceutics.

If you plan to attend this conference, please start an online conversation with us. Our delegates look forward to meeting you in person and answering your questions. For more information about the conference, please visit the following website: https://2024.febscongress.org/.

The 2024 ASCO Annual Meeting will take you to discover state-of-the-art research, groundbreaking treatments, and visionary insights, igniting your passion for oncology. This year's program will feature over 200 sessions, complementing Dr. Lynn Schuchter’s Presidential theme “The Art and Science of Cancer Care: From Comfort to Cure”.

The following MDPI journals will be represented:

• Cancers;
• JPM;
• Pharmaceutics;
• Healthcare;
• JCM;
• CIMB;
• Medical Sciences;
• Clinics and Practice;
• Onco;
• Current Oncology;
• Dermato;
• Pharmacy;
• Biomedicines;
• Diseases;
• Immuno;
• Biologics;
• Vaccines;
• Diagnostics;
• Hemato;
• Venereology.

If you are attending this conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at the booth at the conference and answering any questions you may have. For more information regarding the conference, please visit the following link: https://conferences.asco.org/am/attend.

A welcome message from Dr. Fábio Fernandes, the webinar chair: